Latest1 information on COVID-19

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Not Recruiting

Trial ID: NCT00665561

Age - 18 Years-N/A Condition - Hiv Gender - All Accepting Healthy Volunteers - No

Purpose

The study will assess if use of maraviroc along with an optimized background regimen of antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen of antiretroviral drugs.

Official Title

AN INTERNATIONAL, MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY OF THE SAFETY OF MARAVIROC USED WITH OPTIMIZED BACKGROUND THERAPY IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS

Stanford Investigator(s)

Philip Grant
Philip Grant

Assistant Professor of Medicine (Infectious Diseases)

Andrew Zolopa

Eligibility


Inclusion Criteria:

   - Treatment experienced, HIV-1 infected patients

   - 18 years or older

   - Receive an approved assay for determination of HIV-1 tropism

Exclusion Criteria:

   - Pregnant or lactating

   - Using CCR5 inhibitor other than maraviroc

View More
View Less

Intervention(s):

drug: Maraviroc along with an optimized background antiretroviral drug regimen

drug: Optimized background antiretroviral drug regimen without maraviroc

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Debbie Slamowitz
(650) 723-2808

©2022 Stanford Medicine